PDF(Pubmed)
Abstract：
UNASSIGNED: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders.
UNASSIGNED: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders.
UNASSIGNED: This was a retrospective and multicentre study.
UNASSIGNED: We included patients diagnosed with inflammatory pouch disorders treated with azathioprine in monotherapy. Effectiveness was evaluated at 1 year and in the long term based on normalization of stool frequency, absence of pain, faecal urgency or fistula discharge (clinical remission), or any improvement in these symptoms (clinical response). Endoscopic response was evaluated using the Pouchitis Disease Activity Index (PDAI).
UNASSIGNED: In all, 63 patients were included [54% males; median age, 49 (28-77) years]. The therapy was used to treat pouchitis (n = 37) or Crohn\'s disease of the pouch (n = 26). The rate of clinical response, remission and non-response at 12 months were 52%, 30% and 18%, respectively. After a median follow-up of 23 months (interquartile range 11-55), 19 patients (30%) were in clinical remission, and 45 (66%) stopped therapy. Endoscopic changes were evaluated in 19 cases. PDAI score decreased from 3 (range 2-4) to 1 (range 0-3). In all, 21 patients (33%) presented adverse events and 16 (25%) needed to stop therapy.
UNASSIGNED: Azathioprine may be effective in the long term for the treatment of inflammatory pouch disorders and could be included as a therapeutic option.
UNASSIGNED: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders.
UNASSIGNED: This was a retrospective and multicentre study.
UNASSIGNED: We included patients diagnosed with inflammatory pouch disorders treated with azathioprine in monotherapy. Effectiveness was evaluated at 1 year and in the long term based on normalization of stool frequency, absence of pain, faecal urgency or fistula discharge (clinical remission), or any improvement in these symptoms (clinical response). Endoscopic response was evaluated using the Pouchitis Disease Activity Index (PDAI).
UNASSIGNED: In all, 63 patients were included [54% males; median age, 49 (28-77) years]. The therapy was used to treat pouchitis (n = 37) or Crohn\'s disease of the pouch (n = 26). The rate of clinical response, remission and non-response at 12 months were 52%, 30% and 18%, respectively. After a median follow-up of 23 months (interquartile range 11-55), 19 patients (30%) were in clinical remission, and 45 (66%) stopped therapy. Endoscopic changes were evaluated in 19 cases. PDAI score decreased from 3 (range 2-4) to 1 (range 0-3). In all, 21 patients (33%) presented adverse events and 16 (25%) needed to stop therapy.
UNASSIGNED: Azathioprine may be effective in the long term for the treatment of inflammatory pouch disorders and could be included as a therapeutic option.
摘要：
■在囊炎和其他囊袋疾病中，对硫嘌呤的有用性研究甚少。
■评估硫唑嘌呤作为炎症性囊袋疾病维持治疗的有效性和安全性。
■这是一项多中心的回顾性研究。
■我们纳入了以硫唑嘌呤单药治疗的诊断为炎症性囊袋疾病的患者。根据粪便频率的正常化，在1年和长期评估有效性。没有疼痛，粪便急迫或瘘管排出（临床缓解），或这些症状的任何改善（临床反应）。使用Pouchitis疾病活动指数（PDAI）评估内窥镜反应。
■总之，包括63例患者[54%男性；中位年龄，49(28-77)年]。该疗法用于治疗囊炎（n=37）或克罗恩病（n=26）。临床反应率，12个月时缓解和无反应为52%，30%和18%,分别。在中位随访23个月（四分位距11-55）后，19例患者（30%）处于临床缓解期，45（66％）停止治疗。对19例患者进行内镜检查。PDAI评分从3（范围2-4）降至1（范围0-3）。总之,21例（33%）患者出现不良事件，16例（25%）患者需要停止治疗。
■硫唑嘌呤可长期有效治疗炎性囊袋疾病，并可作为治疗选择。
■评估硫唑嘌呤作为炎症性囊袋疾病维持治疗的有效性和安全性。
■这是一项多中心的回顾性研究。
■我们纳入了以硫唑嘌呤单药治疗的诊断为炎症性囊袋疾病的患者。根据粪便频率的正常化，在1年和长期评估有效性。没有疼痛，粪便急迫或瘘管排出（临床缓解），或这些症状的任何改善（临床反应）。使用Pouchitis疾病活动指数（PDAI）评估内窥镜反应。
■总之，包括63例患者[54%男性；中位年龄，49(28-77)年]。该疗法用于治疗囊炎（n=37）或克罗恩病（n=26）。临床反应率，12个月时缓解和无反应为52%，30%和18%,分别。在中位随访23个月（四分位距11-55）后，19例患者（30%）处于临床缓解期，45（66％）停止治疗。对19例患者进行内镜检查。PDAI评分从3（范围2-4）降至1（范围0-3）。总之,21例（33%）患者出现不良事件，16例（25%）患者需要停止治疗。
■硫唑嘌呤可长期有效治疗炎性囊袋疾病，并可作为治疗选择。
